Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2004 19
2005 13
2006 15
2007 10
2008 6
2009 6
2010 2
2011 2
2012 8
2013 4
2014 2
2015 2
2016 3
2017 9
2018 6
2019 7
2020 9
2021 6
2022 8
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Results by year

Filters applied: . Clear all
Page 1
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.
Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O, Brem S, Butowski N, Cannon DM, Chao S, Chheda MG, Fabiano AJ, Forsyth P, Gigilio P, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Merrell R, Mrugala MM, Nagpal S, Nedzi LA, Nevel K, Nghiemphu PL, Parney I, Patel TR, Peters K, Puduvalli VK, Rockhill J, Rusthoven C, Shonka N, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow S. Horbinski C, et al. Among authors: baehring j. J Natl Compr Canc Netw. 2023 Jan;21(1):12-20. doi: 10.6004/jnccn.2023.0002. J Natl Compr Canc Netw. 2023. PMID: 36634606
Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD, Baehring JM. Kaulen LD, et al. Among authors: baehring jm. Curr Treat Options Oncol. 2022 Nov;23(11):1548-1565. doi: 10.1007/s11864-022-01016-5. Epub 2022 Oct 7. Curr Treat Options Oncol. 2022. PMID: 36205806 Review.
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.
Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, Petrecca K, De Vos F, Wick A, Sumrall A, Sahebjam S, Mellinghoff IK, Kinoshita M, Roberts M, Slepetis R, Warad D, Leung D, Lee M, Reardon DA, Omuro A. Lim M, et al. Among authors: baehring j. Neuro Oncol. 2022 Nov 2;24(11):1935-1949. doi: 10.1093/neuonc/noac116. Neuro Oncol. 2022. PMID: 35511454 Free PMC article. Clinical Trial.
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwirtes R, Sampson J, Weller M. Reardon DA, et al. Among authors: baehring j. JAMA Oncol. 2020 Jul 1;6(7):1003-1010. doi: 10.1001/jamaoncol.2020.1024. JAMA Oncol. 2020. PMID: 32437507 Free PMC article. Clinical Trial.
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, Butowski N, Campian JL, Clark SW, Fabiano AJ, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Horbinski C, Junck L, Kaley T, Kumthekar P, Loeffler JS, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Robins I, Rockhill J, Rusthoven C, Shonka N, Shrieve DC, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow SD. Nabors LB, et al. Among authors: baehring j. J Natl Compr Canc Netw. 2020 Nov 2;18(11):1537-1570. doi: 10.6004/jnccn.2020.0052. J Natl Compr Canc Netw. 2020. PMID: 33152694
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G, Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, Khasraw M, Vauleon E, Muragaki Y, Di Giacomo AM, Butowski N, Roth P, Qian X, Fu AZ, Liu Y, Potter V, Chalamandaris AG, Tatsuoka K, Lim M, Weller M. Omuro A, et al. Among authors: baehring j. Neuro Oncol. 2023 Jan 5;25(1):123-134. doi: 10.1093/neuonc/noac099. Neuro Oncol. 2023. PMID: 35419607 Free PMC article. Clinical Trial.
Hypertrophic pachymeningitis.
Hahn LD, Fulbright R, Baehring JM. Hahn LD, et al. Among authors: baehring jm. J Neurol Sci. 2016 Aug 15;367:278-83. doi: 10.1016/j.jns.2016.06.024. Epub 2016 Jun 11. J Neurol Sci. 2016. PMID: 27423604
Neurolymphomatosis.
Baehring J, Cooper D. Baehring J, et al. J Neurooncol. 2004 Jul;68(3):243-4. doi: 10.1023/b:neon.0000033496.29296.a7. J Neurooncol. 2004. PMID: 15332327 No abstract available.
Neurolymphomatosis.
Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH. Baehring JM, et al. Neuro Oncol. 2003 Apr;5(2):104-15. doi: 10.1093/neuonc/nop021. Neuro Oncol. 2003. PMID: 12672282 Free PMC article.
134 results